CSF3 and acute myeloid leukemia: Furthermore, the use of G-CSF to recruit quiescent AML into cell cycle may accelerate the kinetics to achieve “minimal residual disease” status, a triple combination therapy strategy that spares normal long-term hematopoietic stem/progenitor cells (HSPCs) and thereby improves patient recovery.